Latest News and Press Releases

Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at EACCI 2025

Global exclusive agreement expands patent coverage for compound structures and autoimmune uses across major pharmaceutical markets

Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile ...

WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...

WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...

Trethera enlists leading expert in demyelinating diseases to advance TRE-515, a first-in-class drug with FDA Orphan Drug status for ADEM and optic neuritis

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression KT-621...

Leading AI-Powered Immune Profiling Company IMU to Adopt Pluto Workstation for Large-Scale Immune Phenotyping Project Based on UK Patient Big Data

IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a...

Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic...